Aptahem AB (publ)

Stockholm Stock Exchange APTA.ST

Aptahem AB (publ) Price to Sales Ratio (P/S) on January 14, 2025: 5.21

Aptahem AB (publ) Price to Sales Ratio (P/S) is 5.21 on January 14, 2025, a -56.46% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Aptahem AB (publ) 52-week high Price to Sales Ratio (P/S) is 27.30 on February 01, 2024, which is 423.76% above the current Price to Sales Ratio (P/S).
  • Aptahem AB (publ) 52-week low Price to Sales Ratio (P/S) is 2.20 on November 29, 2024, which is -57.79% below the current Price to Sales Ratio (P/S).
  • Aptahem AB (publ) average Price to Sales Ratio (P/S) for the last 52 weeks is 6.54.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Stockholm Stock Exchange: APTA.ST

Aptahem AB (publ)

CEO Mr. Mikael Lindstam
IPO Date April 17, 2015
Location Sweden
Headquarters Norra Vallgatan 58, 4TR
Employees 5
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children's Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.

StockViz Staff

January 15, 2025

Any question? Send us an email